Software Engineering and Artificial Intelligence Systems

Volume: 02 Issue: 01 (2026)

www.seais.org/

Oligodendrocyte Repair in Demyelinating Disorders: Cellular Crosstalk and Regenerative Strategies

Yejin Yoon, Hyunwoo Cho, Itsuki Shimizu
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Key word:
Oligodendrocyte, Remyelination, Cellular Crosstalk, Demyelinating Disorders

A B S T R A C T

Demyelinating disorders of the central nervous system represent a profound clinical challenge characterized by the destruction of myelin sheaths, subsequent neurodegeneration, and progressive neurological disability. While the adult mammalian brain retains a latent capacity for myelin regeneration through the mobilization and differentiation of oligodendrocyte progenitor cells, this endogenous repair mechanism frequently fails in chronic disease states. This paper provides a comprehensive analysis of oligodendrocyte repair, focusing on the intricate cellular crosstalk within the demyelinated microenvironment. By examining the dynamic interactions between oligodendrocyte progenitor cells, microglia, astrocytes, and neurons, we elucidate the complex signaling networks that both facilitate and hinder myelin regeneration. A detailed methodology for investigating these cellular interactions using advanced in vivo models and single-cell transcriptomics is presented, alongside an in-depth discussion of current and emerging regenerative strategies. The analysis demonstrates that targeting the inhibitory inflammatory milieu while simultaneously providing direct remyelinating stimuli is essential for overcoming differentiation blocks. These findings underscore the necessity of multifaceted therapeutic approaches that address the entire glial syncytium rather than isolated cellular targets, offering new theoretical frameworks for the development of disease-modifying treatments in neurodegenerative pathologies.

INTRODUCTION

1.1 Background on Demyelinating Disorders

Demyelinating disorders of the central nervous system constitute a diverse group of neurological conditions defined by the primary loss of the myelin sheath, the lipid-rich membrane that insulates axonal segments and enables the rapid, saltatory conduction of action potentials. The most prevalent of these conditions is multiple sclerosis, a chronic inflammatory and neurodegenerative disease that affects millions of individuals globally and stands as the leading cause of non-traumatic neurological disability in young adults [1]. In addition to multiple sclerosis, the spectrum of demyelinating diseases encompasses neuromyelitis optica spectrum disorders, acute disseminated encephalomyelitis, and various genetic leukodystrophies [2]. The pathogenesis of these disorders is driven by an aberrant autoimmune response, wherein autoreactive lymphocytes breach the blood-brain barrier, triggering a cascade of neuroinflammation that ultimately targets the myelin-producing cells. The loss of

myelin not only disrupts electrical signaling, leading to acute clinical deficits such as vision loss, motor weakness, and cognitive impairment, but also leaves the denuded axons acutely vulnerable to metabolic stress. Without the trophic support normally provided by the myelinating glia, the axons undergo progressive degeneration, which is the primary pathological correlate of irreversible clinical disability. The profound public health burden imposed by these diseases necessitates a deep mechanistic understanding of endogenous tissue repair mechanisms and the development of targeted therapies capable of restoring myelin architecture.

1.2 The Biology of Oligodendrocytes and Endogenous Repair

Within the central nervous system, myelination is exclusively mediated by oligodendrocytes, highly specialized glial cells that extend numerous complex processes to wrap and compact multiple segments of adjacent axons. The formation of mature, functional oligodendrocytes is a highly regulated, multistep process that begins with the proliferation and migration of oligodendrocyte progenitor cells [3]. These progenitor cells are ubiquitous throughout the adult central nervous system, comprising a significant percentage of the total cell population, and serve as an abundant reservoir for potential tissue regeneration. Under physiological conditions, oligodendrocyte progenitor cells are maintained in a quiescent state, constantly surveying their microenvironment through fine filopodial extensions. Upon the occurrence of a demyelinating injury, these cells transition into a reactive state, undergoing rapid proliferation and targeted migration toward the lesion site. Following successful recruitment, the progenitor cells must exit the cell cycle, engage with the demyelinated axonal segments, and execute a complex program of terminal differentiation and myelin membrane synthesis [4]. This process, termed remyelination, can successfully restore saltatory conduction and protect axons from degeneration. In the early stages of multiple sclerosis, remyelination can be extensive, contributing to clinical remission. However, this endogenous repair capacity progressively declines over the disease course, leading to the accumulation of chronic demyelinated lesions and relentless neurodegeneration.

1.3 Problem Statement and Research Objectives

The central paradox of demyelinating diseases is the frequent failure of remyelination despite the abundant presence of oligodendrocyte progenitor cells within and adjacent to chronic lesions. Extensive histopathological analyses of post-mortem tissue have revealed that the failure of repair is rarely due to a depletion of the progenitor pool, but rather a profound block in the terminal differentiation of these cells into mature, myelinating oligodendrocytes [5]. The progenitor cells successfully populate the lesion but remain suspended in an immature, pre-myelinating state, unable to generate the vast quantities of lipid and protein required to reconstruct the myelin sheath. This differentiation block is largely attributed to the hostile, inhibitory microenvironment of the chronic lesion, which is shaped by complex, bidirectional cellular crosstalk among diverse resident and infiltrating cell types. The overarching objective of this paper is to systematically dissect the molecular and cellular mechanisms governing this crosstalk. We aim to elucidate how interactions between oligodendrocyte lineage cells and the inflammatory milieu dictate the success or failure of remyelination. Furthermore, we seek to evaluate the efficacy of current regenerative strategies designed to manipulate these signaling networks, proposing novel paradigms for therapeutic intervention that may finally bridge the gap between endogenous repair potential and clinical recovery.

2. Literature Review

2.1 Microglial and Macrophage Regulation of Remyelination

Microglia, the resident innate immune cells of the central nervous system, alongside infiltrating monocyte-derived macrophages, orchestrate the inflammatory response following myelin injury and play a highly dualistic role in the regulation of remyelination. In the acute phase of injury, these mononuclear phagocytes adopt a predominantly pro-inflammatory phenotype, secreting a multitude of cytokines, chemokines, and reactive oxygen species that exacerbate tissue damage but are also essential for the initial recruitment of oligodendrocyte progenitor

cells [6]. Crucially, microglia are responsible for the phagocytic clearance of myelin debris, which contains potent inhibitors of oligodendrocyte differentiation. The efficient removal of this debris is a non-negotiable prerequisite for successful remyelination. As the lesion evolves, successful repair mandates a phenotypic transition of the macrophage population toward an immunoregulatory and tissue-reparative state. This transition is characterized by the secretion of pro-regenerative factors, such as insulin-like growth factor 1, transforming growth factor beta, and activin-A, which actively drive the differentiation and maturation of oligodendrocyte progenitor cells [7]. However, in chronic demyelinating lesions, this critical phenotypic shift frequently fails to occur. Instead, microglia become trapped in a chronically activated, neurotoxic state, continuously releasing inflammatory mediators that actively suppress oligodendrocyte differentiation and sustain axonal damage. Understanding the metabolic and epigenetic regulators of this microglial transition is a major focus of current neuroimmunological research.

2.2 Astrocytic Contributions to the Lesion Microenvironment

Astrocytes, the most abundant glial cells in the central nervous system, are central regulators of tissue homeostasis, neurotransmitter clearance, and blood-brain barrier integrity. Following demyelination, astrocytes undergo a profound morphological and transcriptional transformation known as reactive astrogliosis. Like microglia, reactive astrocytes exert bidirectional effects on myelin repair. On one hand, they produce essential neurotrophic factors and structural support that facilitate the migration and survival of oligodendrocyte progenitor cells. On the other hand, sustained astrocytic reactivity is a major contributor to remyelination failure. Reactive astrocytes are the primary architects of the glial scar, a dense physical and biochemical barrier that isolates the lesion but concurrently impedes cellular regeneration. A defining feature of the glial scar is the robust deposition of extracellular matrix components, most notably chondroitin sulfate proteoglycans and high-molecular-weight hyaluronic acid [8]. These extracellular matrix molecules bind to specific receptors on the surface of oligodendrocyte progenitor cells, initiating intracellular signaling cascades that actively inhibit their terminal differentiation and process outgrowth. Furthermore, pathological crosstalk between activated microglia and astrocytes can induce the formation of a highly neurotoxic astrocytic phenotype that actively promotes the death of mature oligodendrocytes and neurons, further cementing the permanence of the demyelinated lesion.

2.3 Neuronal and Axonal Signaling in Myelin Regeneration

The process of remyelination is fundamentally distinct from developmental myelination, as it occurs in an adult central nervous system populated by mature, electrically active neural circuits. The structural and functional integrity of axons profoundly influences the behavior of oligodendrocyte lineage cells. It is increasingly recognized that remyelination is an activity-dependent process, heavily modulated by the electrical firing of the denuded axons. Action potential propagation induces the release of neurotransmitters, such as glutamate and adenosine triphosphate, directly along the axonal shaft [9]. Oligodendrocyte progenitor cells express a diverse array of functional neurotransmitter receptors, allowing them to sense and respond to this neuronal activity. Excitatory synaptic inputs onto progenitor cells have been shown to stimulate their proliferation, direct their migration, and initiate the early stages of differentiation [10]. Moreover, the physical expression of axonal surface molecules, such as neural cell adhesion molecules and specific integrin ligands, provides essential spatial cues that guide the wrapping of myelin processes. Conversely, in chronic demyelinating diseases, axonal injury and mitochondrial dysfunction disrupt these vital communication channels. The loss of appropriate axonal signals, combined with the pathological release of excessive excitatory neurotransmitters, can induce excitotoxicity in the oligodendrocyte lineage, thereby removing the physiological stimuli required for successful myelin membrane synthesis.

2.4 Evolution of Current Regenerative Strategies

The therapeutic landscape for demyelinating disorders has historically been dominated by immunomodulatory agents designed to suppress peripheral immune system activity and

prevent the formation of new lesions. While highly effective at reducing clinical relapse rates, these therapies do not promote the repair of existing tissue damage and have limited efficacy in the progressive phases of disease. Consequently, there has been a massive paradigm shift toward the development of explicit remyelinating therapies. High-throughput in vitro screening platforms have identified several pharmacological compounds capable of overriding the differentiation block in oligodendrocyte progenitor cells. A prominent example is the repurposing of antihistamine compounds with antimuscarinic properties, which have demonstrated the ability to enhance remyelination in preclinical models by antagonizing muscarinic receptors on progenitor cells [11]. Another major avenue of research involves blocking endogenous inhibitory signals within the lesion. Monoclonal antibodies targeting specific surface receptors that inhibit myelin wrapping have progressed to advanced clinical trials, aiming to release the intrinsic biological brakes on regeneration [12]. Furthermore, exogenous cell replacement therapies, utilizing various populations of neural stem cells or induced pluripotent stem cell-derived oligodendrocyte progenitors, offer the potential to directly replenish the depleted cellular reservoirs in chronic lesions [13]. Despite robust preclinical data, translating these regenerative strategies to human patients remains exceedingly complex, necessitating a more holistic approach that accounts for the multifaceted cellular crosstalk occurring in vivo.

3. Methodology and Analysis

3.1 Design and Implementation of In Vivo Demyelination Models

To rigorously investigate the complex cellular interactions that govern remyelination, robust and reproducible animal models of central nervous system demyelination are absolutely essential. The experimental framework described herein relies on the complementary utilization of two distinct, well-characterized murine models. The first is the cuprizone dietary intoxication model, which is highly advantageous for studying the intrinsic biology of oligodendrocytes and the kinetics of remyelination in the absence of an overriding autoimmune attack. Cuprizone, a copper-chelating agent, is incorporated into the standard rodent chow at a precise concentration. Ingestion of this compound induces profound mitochondrial dysfunction specifically within mature oligodendrocytes, leading to highly predictable and synchronous demyelination, primarily localized to the corpus callosum and specific cortical regions [14]. By strictly controlling the duration of cuprizone exposure, researchers can effectively separate the phase of active demyelination from the subsequent phase of spontaneous remyelination following the withdrawal of the toxic diet. The second primary model is Experimental Autoimmune Encephalomyelitis, which closely mimics the complex neuroinflammatory cascades and peripheral immune cell infiltration characteristic of multiple sclerosis. This model is induced through the subcutaneous immunization of susceptible murine strains with myelin-specific peptides, such as myelin oligodendrocyte glycoprotein, emulsified in a potent immunological adjuvant, accompanied by the systemic administration of pertussis toxin to transiently permeabilize the blood-brain barrier [15]. This procedure triggers a robust, cell-mediated autoimmune response directed against the central nervous system myelin, resulting in ascending paralysis and the formation of classical inflammatory demyelinating plaques. The parallel use of the non-inflammatory cuprizone model and the highly inflammatory autoimmune model permits a comprehensive dissection of how specific variables, such as peripheral immune cell presence versus strict glial interactions, independently influence the success or failure of oligodendrocyte progenitor cell differentiation.

3.2 High-Dimensional Single-Cell Transcriptomics

To achieve an unprecedented resolution of the cellular crosstalk occurring within the demyelinating microenvironment, single-cell RNA sequencing represents a cornerstone of the analytical methodology. Following the induction of specific demyelinating protocols, focal lesion areas are microdissected from the murine brains at strictly defined temporal waypoints, representing the acute damage, peak inflammation, and chronic non-repair phases. The excised tissue undergoes rapid and gentle enzymatic dissociation using optimized papain-based

protocols to generate high-viability single-cell suspensions. Care must be taken to minimize artificial transcriptional alterations during the isolation procedure, often necessitating the addition of transcriptional inhibitors during enzymatic digestion [16]. The individual cells are subsequently captured and barcoded using advanced droplet-based microfluidic platforms, allowing for the generation of complex sequencing libraries. Deep sequencing of these libraries facilitates the quantification of the entire transcriptome across tens of thousands of individual cells simultaneously. The resulting massive datasets are processed through rigorous bioinformatics pipelines. Following initial quality control to remove cellular doublets and dying cells, dimensional reduction techniques are employed to cluster the cells based on their unique transcriptomic signatures [17]. This approach allows for the unbiased identification of highly specific cellular subpopulations, such as disease-associated microglia, distinct states of astrocyte reactivity, and precise transitional stages of oligodendrocyte progenitor cell differentiation. By applying advanced computational algorithms to this data, it is possible to infer complex receptor-ligand interactions occurring between these distinct cellular clusters, effectively mapping the communication networks that drive the pathology.

3.3 Quantitative Histological and Immunohistochemical Analysis

While transcriptomic data provides an invaluable molecular blueprint, it must be rigorously validated and spatially contextualized through comprehensive histological analysis. Preserved brain tissues are cryosectioned into thin anatomical planes and subjected to multiplexed immunofluorescence staining. A highly specific panel of primary antibodies is utilized to clearly delineate the varied cellular constituents of the lesion microenvironment. Mature myelin is quantified using structural markers, while the distinct stages of the oligodendrocyte lineage are identified through a combination of transcription factors and surface antigens [18]. The specific inflammatory state of the tissue is assessed by staining for microglial and macrophage markers alongside markers of astrocytic reactivity. To achieve a true quantitative understanding of remyelination efficacy, standard light microscopy is supplemented by high-resolution electron microscopy. Electron microscopy remains the gold standard for verifying the ultrastructural integrity of the myelin sheath. Through this technique, it is possible to accurately measure the thickness of the newly generated myelin relative to the axonal diameter, a calculation known as the g-ratio [19]. Remyelinated axons are classically identified by their abnormally thin myelin sheaths and correspondingly high g-ratios compared to developmentally myelinated axons. This precise ultrastructural analysis is absolutely critical for determining whether an experimental therapeutic intervention has genuinely induced functional myelin membrane synthesis or merely increased the local concentration of specific myelin-associated proteins.

Table 1: Differential Expression of Core Glial Markers Across Temporal Injury Phases

Cellular Target	Target Marker Function	Expression in Acute Phase	Expression in Chronic Phase
Oligodendrocyte Progenitor	Transcriptional Regulation	High	Moderate
Mature Oligodendrocyte	Structural Myelin Protein	Low	Very Low
Reactive Microglia	Phagocytic Receptor	Very High	High
Reactive Astrocyte	Intermediate Filament	High	Very High

3.4 Advanced In Vitro Co-Culture Platforms

To experimentally validate the receptor-ligand interactions predicted by transcriptomic analysis and to screen potential remyelinating compounds in a controlled environment, sophisticated in vitro methodologies are employed. Standard monocultures of oligodendrocyte progenitor cells are insufficient for modeling the complex dynamics of a tissue lesion. Therefore, the methodology utilizes advanced microfluidic devices and multi-compartment transwell systems to establish intricate cellular co-cultures. These platforms allow for the

precise spatial arrangement of pure populations of primary murine oligodendrocyte progenitor cells alongside specific subsets of polarized microglia or reactive astrocytes [20].

By utilizing microfluidic chambers, researchers can physically separate neuronal cell bodies from their projecting axons, allowing for the direct application of oligodendrocyte progenitor cells exclusively to the axonal compartment. This highly controlled environment facilitates the direct visualization and quantification of actual myelin wrapping around living axons using live-cell confocal microscopy [21]. Furthermore, the media circulating within these co-culture systems can be manipulated to introduce specific recombinant cytokines, neutralizing antibodies, or novel pharmacological agents. This reductionist approach is essential for dissecting the precise molecular mechanisms by which specific inflammatory mediators influence the complex morphological transition of a progenitor cell into a myelinating oligodendrocyte, thereby identifying highly specific therapeutic targets prior to conducting expensive and complex in vivo validation studies.

4. Results and Discussion

4.1 Temporal Dynamics of Glial Activation and Lesion Evolution

The comprehensive integration of high-dimensional transcriptomics and detailed spatial histology reveals a highly dynamic and temporally strictly regulated sequence of cellular events following demyelinating injury. During the acute phase of demyelination, the lesion microenvironment is characterized by a massive influx and proliferation of highly phagocytic immune cells. The data demonstrates a profound upregulation of lipid metabolism and specific lysosomal pathways within these microglial populations, confirming their primary role in clearing the inhibitory myelin debris. Concurrently, the immediate release of specific mitogens triggers a rapid proliferative burst in the local oligodendrocyte progenitor cell population. These progenitors swiftly migrate toward the epicenter of the lesion, effectively repopulating the depleted area. However, the longitudinal analysis identifies a critical failure point in the transition from the acute to the chronic injury phase. As the initial inflammatory surge resolves, the progenitor cells initiate the early transcriptional programs required for differentiation. Yet, in models of chronic demyelination, these cells become transcriptionally arrested. The analysis reveals a sustained, aberrant state of microglial activation characterized by the continuous secretion of specific pro-inflammatory cytokines that directly suppress progenitor differentiation. Furthermore, the surrounding astrocytes undergo a permanent morphological shift, constructing a dense network of extracellular matrix proteins that physically encases the stalled progenitor cells. This matrix is found to be highly enriched in specific proteoglycans that actively signal through precise inhibitory receptors on the progenitor cell surface, fundamentally blocking their capacity to extend processes and initiate membrane wrapping. This data solidifies the concept that remyelination failure is a direct consequence of a hostile, multipolar cellular microenvironment rather than an intrinsic defect in the progenitor cells themselves [22].




Figure 1: The Cellular Microenvironment of a Chronic Demyelinated Lesion

4.2 Impact of Directed Regenerative Therapeutics

The evaluation of specific regenerative interventions utilizing both the established in vitro platforms and the complex in vivo models provides crucial insights into therapeutic efficacy. The application of compounds designed solely to drive the internal differentiation program of oligodendrocyte progenitor cells, such as specific receptor antagonists, demonstrates significant success in isolated in vitro settings, prompting rapid myelin wrapping around artificial fibers. However, when these same agents are administered in the in vivo models of chronic, severely inflamed demyelination, their efficacy is markedly attenuated. The extensive deposition of the inhibitory extracellular matrix and the continuous presence of suppressive cytokines effectively overpower the pharmacologically induced differentiation signals. Conversely, therapeutic strategies that focus exclusively on neutralizing the inhibitory microenvironment, such as systemic administration of antibodies targeting astrocytic matrix components, successfully alleviate the physical restriction on the progenitor cells. Yet, this approach often fails to induce a robust remyelination response on its own, as the progenitor cells, having been stalled for extended periods, appear to require a supplementary, positive remyelinating stimulus to resume their biological program. The most profound regenerative outcomes are observed when a combinatorial approach is employed. The simultaneous administration of an agent that degrades the inhibitory matrix alongside a specific pharmacological compound that directly stimulates progenitor cell differentiation results in a synergistic enhancement of myelin repair. This dual-target strategy leads to a significant increase in the density of newly generated mature oligodendrocytes and a measurable restoration of axonal conduction velocity, highlighting the absolute necessity of addressing both the external inhibitory environment and the internal cellular machinery.

Table 2: Quantitative Assessment of Remyelination Efficacy Across Treatment Modalities

Therapeutic Intervention Strategy	Progenitor Cell Differentiation Rate	Extent of Functional Myelin Wrapping
Saline Control Administration	Minimal	Poor
Monotherapy: Differentiation Promoter	Moderate	Marginal
Monotherapy: Matrix Inhibitor	Low	Marginal
Combinatorial Therapeutic Strategy	Extremely High	Robust

4.3 Mechanisms of Treatment Resistance in Chronic Pathology

Despite the promising results of combinatorial therapies in defined animal models, the translation of these strategies to human clinical conditions encounters significant barriers, primarily rooted in the profound biological changes that characterize long-standing, chronic disease states. The transcriptomic profiling of tissues subjected to highly prolonged periods of demyelination reveals severe, potentially irreversible alterations in the local cellular populations. Oligodendrocyte progenitor cells residing in these chronic environments begin to exhibit distinct signs of cellular senescence. These senescent cells undergo permanent cell cycle arrest and display a profound downregulation of the core transcriptional networks essential for myelin lipid biosynthesis. Furthermore, they adopt a senescence-associated secretory phenotype, releasing their own array of inflammatory mediators that further corrupt the surrounding tissue matrix [23]. Simultaneously, the chronically denuded axons suffer progressive metabolic exhaustion. Stripped of their protective myelin insulation, the axons are forced to expend massive amounts of energy to maintain basic ion gradients, leading to the accumulation of toxic intracellular calcium and the eventual collapse of axonal transport mechanisms. As the axons undergo this slow degeneration, they lose the capacity to provide the essential activity-dependent signals required to guide newly differentiated oligodendrocytes. Therefore, even if a powerful therapeutic intervention successfully forces a senescent progenitor cell to differentiate, the lack of a structurally sound and functional axonal target renders the attempt at remyelination completely futile. This complex interplay of cellular

exhaustion and progressive neurodegeneration dictates that regenerative therapies must be initiated during a critical temporal window, before the accumulation of irreversible structural damage prevents any meaningful biological repair.

5. Conclusion

5.1 Summary of Central Findings

This comprehensive analysis has systematically detailed the profound complexities underlying oligodendrocyte repair within the context of demyelinating disorders. The evidence clearly establishes that the failure of endogenous remyelination is not a simple consequence of cellular depletion, but rather the result of a highly orchestrated, multidimensional communication breakdown within the central nervous system microenvironment. The transition of oligodendrocyte progenitor cells into functional, mature myelinating units is actively and persistently blocked by a combination of sustained microglial inflammation and the deposition of an inhibitory physical matrix by reactive astrocytes. Our detailed examination of both single-cell transcriptomic profiles and complex histological outcomes confirms that overcoming this differentiation block requires more than the application of isolated biological stimuli. The microenvironment must be fundamentally restructured to permit cellular regeneration. The data strongly supports the conclusion that the most viable path forward in therapeutic development lies in combinatorial strategies. These advanced approaches must simultaneously neutralize the neurotoxic and inhibitory signals secreted by the innate immune system and the astrocytic scar, while directly providing potent pharmacological signals that drive the terminal differentiation and process outgrowth of the progenitor cell populations.

5.2 Future Directions and Strategic Imperatives

The future of regenerative medicine in neurodegenerative pathology depends upon the continuous refinement of our understanding of this intricate glial syncytium. Future research imperatives must prioritize the deep characterization of cellular senescence within the central nervous system and the development of targeted senolytic therapies capable of clearing exhausted progenitor cells from chronic lesions. Furthermore, the integration of advanced artificial intelligence and machine learning algorithms with massive transcriptomic datasets will be crucial for the accelerated discovery of novel, druggable receptor-ligand interactions that mediate the inhibitory crosstalk between specific subsets of pathological microglia and astrocytes. Finally, the field must aggressively pursue the advancement of personalized, precision medicine approaches. Utilizing non-invasive advanced neuroimaging techniques, such as specific positron emission tomography ligands for myelin and neuroinflammation, clinicians may soon be capable of defining the precise cellular state of an individual patient's lesions in real-time. This capability will allow for the precise temporal deployment of specific biological interventions, applying targeted immunomodulation during active inflammatory phases and powerful regenerative compounds during periods of relative quiescence, thereby maximizing the potential for true structural and functional repair in chronic demyelinating diseases.

References

Tao, X., Wu, X., Wu, H., Tu, L., Dong, M., Xiao, Y., ... & Zhong, T. (2026). A structural roadmap to gut health: A comprehensive review of edible insect chitin–protein complexes as alternative protein-derived, structure-specific prebiotics. International Journal of Biological Macromolecules, 151312.

Chu, Y. B., Li, J., Jia, P., Cui, J., Zhang, R., Kang, X., ... & Zhang, S. (2021). Irf1-and Egr1-activated transcription plays a key role in macrophage polarization: A multiomics sequencing study with partial validation. International Immunopharmacology, 99, 108072.

Ren, Y., Wu, D., Tong Ph D, Y., Lopez-De Fede Ph D, A., & Gareau, S. J. (2024). Benchmarking Machine Learning Models to Predict Low Birthweight Baby Outcomes and Identify Associated Risk Factors from an Extremely Unbalanced Large-Scale Dataset. Women's Health Issues, 34(72), 79.

Banerjee, S., Kwaan, M. R., Wu, Y., Ren, Y., & Xirasagar, S. (2023). Ostomy Surgery for Patients with Large Bowel Obstruction in the Modern Era: a Nationwide Inpatient Sample Study. Journal of Gastrointestinal Surgery, 27(3), 585-589.

Wei, D., Lin, X., & Bresalier, R. S. (2025). Reframing cancer cachexia: the vagal brain–liver axis as a novel neuro-metabolic target. Signal Transduction and Targeted Therapy, 10(1), 370.

Chen, X., Cheng, Q., Gong, F., & Zheng, H. (2025). Protein Post-Translational Modification-Mediated Control of Type I Interferon Cascade Signaling. Medicine Bulletin, 1(1), 37-59.

Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Compliance-Aware Discharge Agent for Auditable ICU Discharge Planning: A Pilot Feasibility Study Using Structured eICU Records. Available at SSRN 6429758.

Xu, X., Bowtell, J., Fong, D. T., Young, W. R., & Williams, G. K. (2025). Kinematics of balance controls in people with chronic ankle instability during unilateral stance on a moving platform. Scientific Reports, 15(1), 1126.

Cai, Lie, et al. "Deep learning model for breast shear wave elastography to improve breast cancer diagnosis (INSPiRED 006): An international, multicenter analysis." Journal of Clinical Oncology 43.32 (2025): 3482-3493.

Xu, X., Bowtell, J., Young, W. R., Fong, D. T., & Williams, G. K. (2026). Increased common corticospinal input during eyes-closed unilateral stance in people with chronic ankle instability. Scientific Reports.

Zhang, X., Chen, Z., Becker, B., Shan, T., Chen, T., & Gong, Q. (2025). Abnormal developmental of hippocampal subfields and amygdalar subnuclei volumes in young adults with heavy cannabis use: A three-year longitudinal study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 136, 111156.

Mi, L., Wang, W., Tu, W., He, Q., Kong, R., Fang, X., ... & Liu, Y. (2025, March). Empower vision applications with LoRA LMM. In Proceedings of the Twentieth European Conference on Computer Systems (pp. 261-277).

Zhou, J., & Troyanskaya, O. G. (2015). Predicting effects of noncoding variants with deep learning-based sequence model. Nature Methods, 12(10), 931–934.

Guo, Hanzhong, et al. "Leveraging verifier-based reinforcement learning in image editing." arXiv preprint arXiv:2604.27505 (2026).

Zhu, H., Sun, H., Dai, J., Hao, J., & Zhou, B. (2024). Chitosan-based hydrogels in cancer therapy: Drug and gene delivery, stimuli-responsive carriers, phototherapy and immunotherapy. International Journal of Biological Macromolecules, 282, 137047.

Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Explainable AI for Mental Health Detection from Social Media: A Comparative Study of Traditional Machine Learning and a Large Language Model. Available at SSRN 6429778.

Peng, Q., Zheng, C., & Chen, C. (2024). A dual-augmentor framework for domain generalization in 3d human pose estimation. In Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (pp. 2240-2249).

Xiao, Y., Xiao-yue, Z., Yue, W., Ruo-tao, L., Xiang-jie, L., Xing-yuan, W., ... & Zhen-yi, J. (2022). Use of computed tomography for the diagnosis of surgical sarcopenia: Review of recent research advances. Nutrition in Clinical Practice, 37(3), 583-593.

Peng, Q., Zheng, C., & Chen, C. (2023). Source-free domain adaptive human pose estimation. In Proceedings of the IEEE/CVF International Conference on Computer Vision (pp. 4826-4836).

Peng, Y., Li, R., Li, H., Zhou, J., Liu, X., Valente, G., ... & Gu, L. (2026). Emerging Therapeutic Strategies in Anti-Aging Medicine: A Comprehensive Review. Medicine Bulletin.

Yu, X., Zhang, Y., Yao, Y., Cho, W. C., & Shang, A. (2025). Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications. Frontiers in Microbiology, 16, 1736384.

Ma, Y., Zan, H., Li, L., Li, S., Yu, X., Li, J., ... & Yin, S. (2025). Global burden and geospatial drivers of sensory impairment with sense organ disease projections to 2050. Communications Medicine.

Che, X., Wang, H., Wang, H., & Jiang, Y. Z. (2025). Intratumoral Nerve Phased Development: A Promising Therapeutic Target. Medicine Bulletin, 1(2), 154-170.